Esophageal Squamous Cell Carcinoma (ESCC) is an indication for drug development with over 150 pipeline drugs currently active. According to GlobalData, preregistered drugs for Esophageal Squamous Cell Carcinoma (ESCC) have a 80% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Esophageal Squamous Cell Carcinoma (ESCC) compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Esophageal Squamous Cell Carcinoma (ESCC) overview

Esophageal squamous cell carcinoma (ESCC) is a type of cancer that arises from the squamous cells lining the esophagus, the muscular tube connecting the throat to the stomach. Commonly associated with tobacco and alcohol use, as well as dietary factors, ESCC is prevalent in certain geographic regions. Symptoms often manifest late and include difficulty swallowing, weight loss, and chest pain. Diagnosis involves endoscopic procedures, biopsies, and imaging studies. Treatment modalities range from surgery and chemotherapy to radiation therapy, depending on the cancer’s stage and extent. Prognosis is generally guarded, underscoring the importance of early detection and comprehensive management strategies.

For a complete picture of PTSR and LoA scores for drugs in Esophageal Squamous Cell Carcinoma (ESCC), buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.